[go: up one dir, main page]

MX2017011990A - Metodo de preparacion de la forma a cristalina de pci-32765. - Google Patents

Metodo de preparacion de la forma a cristalina de pci-32765.

Info

Publication number
MX2017011990A
MX2017011990A MX2017011990A MX2017011990A MX2017011990A MX 2017011990 A MX2017011990 A MX 2017011990A MX 2017011990 A MX2017011990 A MX 2017011990A MX 2017011990 A MX2017011990 A MX 2017011990A MX 2017011990 A MX2017011990 A MX 2017011990A
Authority
MX
Mexico
Prior art keywords
pci
crystal form
crystal
preparation
solution
Prior art date
Application number
MX2017011990A
Other languages
English (en)
Inventor
Zhang Liang
Zhang Yanfeng
Chen Minhua
Ji Shulin
Original Assignee
Crystal Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Publication of MX2017011990A publication Critical patent/MX2017011990A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N25/00—Investigating or analyzing materials by the use of thermal means
    • G01N25/20—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity
    • G01N25/48—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation
    • G01N25/4846—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample
    • G01N25/4866—Investigating or analyzing materials by the use of thermal means by investigating the development of heat, i.e. calorimetry, e.g. by measuring specific heat, by measuring thermal conductivity on solution, sorption, or a chemical reaction not involving combustion or catalytic oxidation for a motionless, e.g. solid sample by using a differential method

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describe un método de preparación de una Forma A cristalina de PCI-32765. El método de preparación comprende las siguientes etapas: 1) disolver un sólido alcalino libre de PCI-32765 en un solvente positivo; 2) agregar gota a gota la solución de la etapa 1) en un anti-solvente, agitar después que se completa el agregado gota a gota, y agregar una semilla de cristal de la forma A de cristal PCI-32765, o agregar la solución de la etapa 1) en un líquido de suspensión que contiene la semilla de cristal de la forma A de cristal PCI-32765; 3) controlar el sistema de solución obtenido en la etapa 2) para agitar continuamente, y madurar para obtener magma de cristal; y 4) filtrar, lavar y secar el magma de cristal para obtener polvo de la forma A de cristal PCI-32765. El método de preparación tiene las características de simplicidad en la operación de proceso, proceso estable y controlable, alto rendimiento, protección ambiental, buena capacidad de remoción de impurezas e idoneidad para producción industrial. Además, la forma A de cristal preparada puede almacenarse establemente, y la higroscopicidad y la solubilidad de la forma A de cristal preparada reúne los requerimientos para uso medicinal.
MX2017011990A 2015-03-20 2016-03-18 Metodo de preparacion de la forma a cristalina de pci-32765. MX2017011990A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510126412 2015-03-20
PCT/CN2016/076779 WO2016150349A1 (zh) 2015-03-20 2016-03-18 一种pci-32765晶型a的制备方法

Publications (1)

Publication Number Publication Date
MX2017011990A true MX2017011990A (es) 2018-06-06

Family

ID=56310982

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011990A MX2017011990A (es) 2015-03-20 2016-03-18 Metodo de preparacion de la forma a cristalina de pci-32765.

Country Status (9)

Country Link
US (1) US10138239B2 (es)
EP (1) EP3272753B1 (es)
JP (1) JP6657269B2 (es)
CN (1) CN105669679A (es)
AU (1) AU2016236578B2 (es)
CA (1) CA2980418C (es)
IL (1) IL254530A0 (es)
MX (1) MX2017011990A (es)
WO (1) WO2016150349A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
CN106831788B (zh) * 2017-01-22 2020-10-30 鲁南制药集团股份有限公司 伊布替尼精制方法
WO2019070698A1 (en) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company Novel forms of ibrutinib
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
CN115639091B (zh) * 2022-12-21 2023-03-17 南通嘉鹏新材料科技有限公司 一种聚酯热熔胶的硬度检测设备

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX348290B (es) * 2012-06-04 2017-06-05 Pharmacyclics Llc Formas cristalinas de un inhibidor de tirosina quinasa de bruton.
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
RU2702908C2 (ru) * 2012-11-01 2019-10-14 Инфинити Фармасьютикалз, Инк. Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
CN103694241A (zh) * 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法

Also Published As

Publication number Publication date
US20180065958A1 (en) 2018-03-08
CA2980418A1 (en) 2016-09-29
US10138239B2 (en) 2018-11-27
JP6657269B2 (ja) 2020-03-04
EP3272753B1 (en) 2020-03-04
CA2980418C (en) 2019-07-09
CN105669679A (zh) 2016-06-15
AU2016236578B2 (en) 2019-04-04
WO2016150349A1 (zh) 2016-09-29
JP2018508584A (ja) 2018-03-29
EP3272753A4 (en) 2018-07-25
IL254530A0 (en) 2017-11-30
EP3272753A1 (en) 2018-01-24
AU2016236578A1 (en) 2017-10-12

Similar Documents

Publication Publication Date Title
MX2017011990A (es) Metodo de preparacion de la forma a cristalina de pci-32765.
EP4450129A3 (en) Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
EP4566676A3 (en) Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
WO2016161989A3 (zh) 一种硫酸氢氯吡格雷i晶型球形结晶的制备方法
MX2018006969A (es) Método de preparación de la forma ii hidrato del cocristal de valasartán y ahu-377 trisódico.
GB201319253D0 (en) Extraction of carboxylic acids with tin compounds
PH12020500586A1 (en) Process for preapring large size isoxazoline particles
JP2014520848A5 (es)
CN101704766B (zh) 精氨酸阿司匹林及其粉针剂的制备方法
MX2018005803A (es) Forma novedosa de espirodiclofeno, procedimiento de preparacion y uso de la misma.
CN103102351B (zh) 一种制备高纯度叶酸的精制方法
AR081267A1 (es) Procedimiento de obtencion de la forma cristalina a del febuxostat
PH12019500435A1 (en) Method for producing scandium compound, and scandium compound
WO2019080017A1 (zh) 一种制备高纯度低危害的番茄红素晶体的方法
JP2015162299A5 (es)
MX2020001348A (es) Proceso para la disolución rápida de polvo que comprende polímero a base de acrilamida de bajo peso molecular.
CN103408495B (zh) 甲磺酸酚妥拉明的合成工艺
CN103288904B (zh) 一种磷酸替米考星晶体的制备方法
CN103167872A (zh) 用于生产l-肉碱酒石酸盐的方法
CN104151324B (zh) 一种溶媒结晶法制备氨苄西林钠的方法
CN105315300B (zh) 一种头孢西丁钠、其制备方法及用途
CN107445878B (zh) 叶黄素晶体及其制备工艺
JP2020502280A5 (es)
RU2013122374A (ru) Препарат, обладающий антитоксической активностью и содержащий комплексное соединение производного метилурацила с органической кислотой, и способ его получения
SG11201811493UA (en) Crystal of amino acid salt of 3-hydroxyisovaleric acid and production method thereof

Legal Events

Date Code Title Description
FG Grant or registration